Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Nov / Giving the GIFT of Genomic Mapping
Discovery & Development Advanced Medicine

Giving the GIFT of Genomic Mapping

Scientists introduce an innovative approach to genomic mapping called genomic informational field theory (GIFT), which could boost our understanding of genotype–phenotype relationships.

By Rob Coker 11/28/2024 4 min read

Share

A team of scientists led by Cyril Rauch and Panagiota Kyratzi at the UK’s University of Nottingham, has introduced genomic informational field theory (GIFT) – a mapping approach that could help improved our understanding of genotype–phenotype relationships. From target identification, drug efficacy, safety, and biomarker development to clinical trial stratification and regulatory considerations, genotype–phenotype relationship knowledge helps researchers tailor drug development to produce safer, more effective, and patient-specific therapies.

GWAS methods have long been the standard for associating genetic variations with phenotypic traits; however, though powerful, these methods rely heavily on statistical averages, leading to certain limitations. By focusing on averages and variances, GWAS can miss critical variations within categories, potentially overlooking subtle but vital genotype–phenotype relationships.

To circumvent these limitations, Rauch, Kyratzi, and their team developed GIFT. Unlike GWAS, which uses a “bottom-up” approach to evaluate gene contributions to traits, GIFT takes a “top-down” approach to assess how phenotypes might select certain genetic expressions or microstates essential for their maintenance. This approach avoids categorizing data into broad groups, instead providing a full information profile.

Through real-world application on two datasets obtained from sheep, the researchers demonstrated that GIFT extracts richer information than GWAS, providing a broader view and revealing multiple significant regions. In the first dataset, GIFT revealed that a bone structure trait was influenced by more than one genetic region, thus presenting it as a “complex trait” rather than a single-gene trait. In a second dataset, GIFT analysis uncovered new insights into the genetic network influencing a complex metabolic cycle. Notably, GIFT identified regulatory variants that GWAS missed, showing that phenotypic effects may be influenced by genetic “paths” or ordered configurations of genetic expression, hinting at deeper regulatory mechanisms within the genome.

GIFT’s top-down methodology means that it could also be applied to phenotypic plasticity — the ability of an organism to change in response to its environment. As the study highlights, GIFT can map genes that may be “waiting” for certain environmental cues to express specific phenotypes. Such information could feed into precision medicine, where understanding the interplay between genetic potential and environmental triggers could lead to more effective interventions.

Moreover, GIFT’s insights into regulatory variants — a class of genes often involved in controlling other genes’ activities — could further enhance gene-editing tools, such as CRISPR, by offering clearer targets for precise interventions.

The researchers emphasize that GIFT doesn’t just complement GWAS; it represents a shift in conceptualizing genetic research. But they also note that further validation in live animal models and human trials is needed before GIFT’s insights can be translated into practical applications. As a first step, researchers plan to investigate if GIFT can map similar regulatory variants in human complex traits.

Credit: AdobeStock.com

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.